Science News from ACC 2020

March 28–30, 2020 | Virtual Conference

Featured science from Sat., March 28


VICTORIA | Paul W Armstrong, MD

Investigator Paul W. Armstrong, MD summarizes the results of the VICTORIA trial which he presented virtually during ACC 2020. VICTORIA examines the use of vericiguat in patients with HFrEF.
See VICTORIA science

 


VOYAGER PAD | Marc Bonaca, MD, MPH

Investigator Marc Bonaca, MD, MPH reports the results of the VOYAGER PAD trial, which examined reducing the risk of adverse limb and cardiovascular outcomes in patients with lower extremity PAD after intervention.
See VOYAGER PAD science

VICTORIA: A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF)
Paul Wayne Armstrong | Canadian VIGOUR Centre, University of Alberta, Edmonton, Canada

VOYAGER PAD: Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities
Marc P. Bonaca | CPC Clinical Research, Aurora, CO

TAILOR-PCI: Tailored Antiplatelet Therapy Following PCI
Naveen L. Pereira | Mayo Clinic, Rochester, MN

COVID-19 Compendium for Professionals: Guidance and Resources

Featured science from Sun., March 29


TAVR Low Risk Bicuspid Study

Co-Principal Investigator Basel Ramlawi, MD summarizes the results of the TAVR Low Risk Bicuspid Study which he presented virtually for ACC 2020. The prospective single-arm interventional study examined TAVR for patients with severe aortic stenosis.
See the TAVR substudy results

CARAVAGGIO: Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer
Giancarlo Agnelli | University of Perugia, Perugia, Italy

POPular-TAVI: Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation
Vincent Nijenhuis | St. Antonius Hospital, Nieuwegein, The Netherlands

Transcatheter Aortic Valve Replacement (TAVR) Low Risk Bicuspid Study
Basel Ramlawi | Valley Health System, Winchester, VA

STS/ACC Transcatheter Valve Therapy Registry
Nimesh Desai | Hospital of the University of Pennsylvania, Philadelphia, PA

UK TAVI: The United Kingdom Transcatheter Aortic Valve ImplantationTrial
William D. Toff | University of Leicester, Leicester, United Kingdom

PARTNER 3: Two-year Clinical And Echocardiographic Outcomes From The Partner 3 Low-risk Randomized Trial
Michael J. Mack | Columbia University Medical Center, New York, NY

Rivaroxaban Versus Enoxaparin In Nonmajor Orthopedic Surgery
Nadia Rosencher | Centre Hospitalier Universitaire de Saint Etienne, Saint Etienne, France

VOYAGER-PAD Subgroup: Rivaroxaban Plus Aspirin In Patients With PAD After Lower Extremity Revascularization (ler) With And Without Concomitant Clopidogrel
William R. Hiatt | CPC Clinical Research, Aurora, CO, USA, University of Colorado School of Medicine, Aurora, CO

Spyral HTN-OFF MED Study
Michael Boehm | Universitaetskllinikum Des Saarlandes, Homberg, Germany

Randomized Clinical Trial Of Pre-hospital Sodium Nitrite In Out-of-hospital Cardiac Arrest Patients
Francis Kim | University of Washington, Department of Medicine, Division of Cardiology, Seattle, WA

PHD image: Coronavirus, COVID-19 (red)Fighting COVID-19

We know that many of you are fighting, both personally and professionally, on the front lines during these uncertain times.

The AHA is committed to supporting your life-saving efforts with COVID-19 resources, research funding opportunities and disseminating the latest in cutting-edge science and clinical practice related to cardiovascular and neurological impacts.

We also are looking towards the future to ensure that we continue to support your work when we return to a state of normalcy because the dissemination of science and new learnings must always continue. In the interim we want to stay connected to the people that we care about as well as news, information, education.

Featured science from Mon., March 30

Ticagrelor With Or Without Aspirin In Acute Coronary Syndrome After Percutaneous Coronary Intervention: Randomized Evaluation Of Ticagrelor Monotherapy After 3-month Dual-antiplatelet Therapy In Acute Coronary Syndrome
Yang Soo Jang | Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, South Korea

  • RESULTS: For ACS patients receiving DES, there were less adverse events with ticagrelor monotherapy after 3 months of DAPT compared to 12 months of ticagrelor-based DAPT.
  • ClinicalTrials.gov Identifier: NCT02494895

The TWILIGHT-COMPLEX Substudy: Safety And Efficacy Of Ticagrelor Monotherapy After Complex PCI
George D. Dangas | Icahn School of Medicine at Mount Sinai, New York, NY

  • RESULTS: In patients after complex PCI, 3 months of DAPT followed by ticagrelor monotherapy for 12 months resulted in less bleeding and no increase in ischemic events compared to ticagrelor + aspirin for 1 year.
  • TWILIGHT ClinicalTrials.gov Identifier: NCT02270242

Radial Artery Versus Saphenous Vein For Coronary Bypass Surgery At Long Term Follow-up
Mario F.L. Gaudino | Weill Cornell Medicine, New York, NY

Ten-year Outcomes After Drug-eluting Stents Versus Coronary Artery Bypass Grafting For Left Main Coronary Disease
Duk-Woo Park | Asan Medical Center, Seoul, South Korea

Ticagrelor With And Without Aspirin In High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: Insights From The TWILIGHT Trial
Dominick Angiolillo | Icahn School of Medicine at Mount Sinai, New York, NY

  • RESULTS: In high-risk patients with DM and having PCI, ticagrelor monotherapy had less clinically significant bleeding and adverse events than ticagrelor and aspirin.
  • ClinicalTrials.gov Identifier: NCT02270242

A Randomized Controlled Trial Evaluating The Efficacy And Safety Of E-Cigarettes For Smoking Cessation
Mark J. Eisenberg | Lady Davis Institute for Medical Research of the Jewish General Hospital, Montreal, Canada, McGill University, Montreal, Canada

ODYSSEY HoFH: Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia
Dirk Blom | Sanofi, Paris, France and Regeneron Pharmaceuticals, Inc., Tarrytown, NY

Evinacumab Significantly Reduces LDL-C In Patients With Homozygous Familial Hypercholesterolemia
Frederick J. Raal | Regeneron Pharmaceuticals, Inc., Tarrytown, NY

  • RESULTS: Significant reduction in LDL-C with evinacumab for HoFH patients.

Eicosapentaenoic Acid Levels in REDUCE-IT and Cardiovascular Outcomes
Deepak L. Bhatt | Brigham and Women's Hospital, Boston, MA

CIAO: Ancillary Study To The ISCHEMIA Trial – Natural History Of Symptoms And Stress Echo Findings In Patients With Moderate Or Severe Ischemia And No Obstructive CAD (INOCA)
Harmony R. Reynolds | NYU School of Medicine, New York, NY